EXELIXIS, INC.

EXEL
Real-time Estimate Quote. Real-time Estimate  - 05/26 02:05:45 pm
18.285USD +2.67%

Turn to zoom
Prev.17.8100
Open17.7800
High18.5900
Low17.7000
Volume1 165 444
Latest news
05/17
05/11
05/10
05/10
Chart EXELIXIS, INC.
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralNeutral
Resistance20,323,223,4
Spread/Res.-12%-23%-24%
Spread/Supp.2,1%12%12%
Support17,415,815,8
Financials
Sales 2022 1 587 M - -
Net income 2022 291 M - -
Net cash 2022 1 276 M - -
P/E ratio 2022 19,9x
Yield 2022 -
Capitalization 5 712 M 5 712 M -
EV / Sales 2022 2,80x
EV / Sales 2023 2,29x
Nbr of Employees 954
Free-Float 97,7%
Company
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is...

>> Read more
Sector :
Bio Therapeutic Drugs
Calendar :
2022-05-25 Shareholder meeting
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 17,81 $
Average target price 26,45 $
Spread / Average Target 48,5%